Stoke Therapeutics files prospectus supplement for up to $200M ATM offering

Stoke Therapeutics, Inc.

Filed prospectus supplement on Aug 3, 2026 to sell up to $200M of common stock.
Shares offered under existing Controlled Equity Offering Sales Agreement with Cantor Fitzgerald.
Prospectus supplement part of automatic shelf registration statement filed March 18, 2026.
Legal opinion of Fenwick & West LLP filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.